Gilead Sciences, Inc. (GILD): Marketing Mix Analysis [June-2026 Updated]

This ready-made late-2025 Marketing Mix Analysis of Gilead Sciences, Inc. gives you a practical, research-based view of how the business sells, reaches, promotes, and prices its portfolio, from Biktarvy’s 70% U.S. share and Veklury’s revenue role to Livdelzi, Trodelvy, and lenacapavir, plus global access through 120+ countries, a 17,000+ workforce, Foster City operations, a $32 billion U.S. buildout, FDA-led launches, PURPOSE 2 and ASCENT-04 messaging, and specialty pricing such as Livdelzi at $12,606 per 30-day supply.

Gilead Sciences, Inc. - Marketing Mix: Product

Biktarvy anchors the HIV franchise, Livdelzi adds 1 oral PBC option, Trodelvy carries the oncology platform, lenacapavir moved through 2 phase 3 HIV-prevention trials, and Veklury stayed the IV COVID-19 antiviral.

• Biktarvy: 3 active ingredients, 1 tablet, 1 daily dose.
• Livdelzi: 10 mg oral dose, 1 time daily.
• Trodelvy: 10 mg/kg, 2 infusion days in each 21-day cycle.
• Lenacapavir: 2 PURPOSE phase 3 trials, 26-week dosing interval.
• Veklury: 200 mg start, then 100 mg maintenance dosing.

Biktarvy

Biktarvy is a 3-drug fixed-dose HIV tablet with bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg. The product is taken as 1 tablet once daily and has been part of Gilead Sciences, Inc.'s HIV portfolio since 2018. Its product design is simple: 1 oral tablet, 3 active agents, and a once-daily schedule.

The combination format matters because it reduces pill count to 1 tablet. In HIV treatment, that makes the product easier to use than multi-pill regimens and keeps it at the center of the company’s HIV mix. The product is also a standard reference point for the rest of the portfolio because it sets the benchmark for oral convenience.

Livdelzi

Livdelzi is an oral primary biliary cholangitis product with a 10 mg once-daily dose and a 2024 U.S. approval. It gives Gilead Sciences, Inc. a non-HIV, non-oncology product inside the liver-disease category.

The product’s value is tied to 1 daily oral dose rather than an infusion or injection. For the marketing mix, that places Livdelzi in the same convenience class as chronic oral therapies, which matters in a disease where long-term adherence is important. The approval year also makes it one of the newer additions to the company’s product set.

Trodelvy

Trodelvy is an IV antibody-drug conjugate dosed at 10 mg/kg on day 1 and day 8 of each 21-day cycle. Its oncology use gives Gilead Sciences, Inc. a product that is structurally different from the HIV and antiviral portfolio because it requires infusion-based administration.

Trodelvy was also being advanced in 1st-line triple-negative breast cancer through phase 3 development. The product is already established in metastatic breast cancer settings, so the first-line program matters because it can widen the number of eligible patients. The dosing schedule and IV route make it a higher-touch product than Biktarvy or Livdelzi.

Lenacapavir

Lenacapavir is the company’s long-acting HIV capsid inhibitor, built around a 26-week dosing interval and a 927 mg subcutaneous dose. In 2024, the prevention program moved through 2 phase 3 PURPOSE trials, PURPOSE 1 and PURPOSE 2.

In PURPOSE 1, the lenacapavir arm recorded 0 HIV infections. That number is the clearest product-level milestone in the prevention portfolio because it links the product directly to a long-duration dosing profile. The combination of a 6-month interval and injectable delivery gives lenacapavir a different product position from daily oral HIV therapy.

Veklury

Veklury is the company’s IV antiviral for COVID-19, with a regimen of 200 mg on day 1 and 100 mg daily after that. The product is used in 3-day and 5-day treatment courses, which keeps it structurally different from chronic oral products.

The product remained part of the company’s antiviral mix because it is delivered by infusion and can be used in short treatment courses rather than long-term maintenance. The dose structure is simple and fully numeric: 200 mg, then 100 mg, then a course length of 3 or 5 days.

Gilead Sciences, Inc. - Marketing Mix: Place

As of late 2025, Gilead Sciences' place strategy centered on a global workforce of 17,000+, voluntary HIV licenses covering 120+ countries, and a U.S. buildout of $32 billion.

Foster City, California stayed a core hub, and the AI-enabled development center broke ground there.

• 17,000+ employees support the operating footprint.
• Foster City, California remains the anchor site.
• Voluntary HIV licenses reach 120+ countries.
• The U.S. buildout equals $32 billion.
• The AI-enabled development center adds capacity in Foster City.

Gilead Sciences, Inc. - Marketing Mix: Promotion

Gilead Sciences, Inc. tied promotion in late 2025 to June 18, 2025, 2 PURPOSE 2 infections in 2,179 participants, a 35% risk reduction readout in ASCENT-04/KEYNOTE-D19, and more than $260 million in philanthropic grants.

FDA approvals anchored product launches

On June 18, 2025, the FDA approved lenacapavir for HIV pre-exposure prophylaxis in adults and adolescents weighing at least 35 kg. The twice-yearly dosing message gave Gilead Sciences, Inc. a promotion platform built around 2 injections a year instead of daily oral PrEP.

• June 18, 2025: FDA approval for HIV pre-exposure prophylaxis
• 35 kg: minimum approved body weight for adolescents
• 2: dosing frequency per year

PURPOSE 2 data lifted lenacapavir profile

PURPOSE 2 included 2,179 participants and recorded 2 HIV infections in the lenacapavir arm. The study showed a 96% lower HIV risk versus background incidence, which gave Gilead Sciences, Inc. a simple data point for medical and public-health promotion.

ASCENT-04 data supported Trodelvy messaging

ASCENT-04/KEYNOTE-D19 was a phase 3 study in first-line PD-L1-positive metastatic triple-negative breast cancer. The data package included a 35% reduction in risk of progression or death, which strengthened oncology promotion for sacituzumab govitecan.

Genesis AI partnership signaled R&D innovation

Gilead Sciences, Inc. kept Genesis Therapeutics in the promotion mix as an AI-based R&D signal in late 2025. The collaboration message linked external innovation with pipeline development, even without a public product launch number attached to it.

Philanthropic grants topped $260 million

Gilead Sciences, Inc. reported more than $260 million in philanthropic grants and charitable support. That number supported promotion around access, community health, and disease awareness.

• 2,179 participants in PURPOSE 2
• 2 infections in the lenacapavir arm
• 96% lower HIV risk in PURPOSE 2
• 35% reduction in progression or death in ASCENT-04/KEYNOTE-D19
• More than $260 million in philanthropic grants

Gilead Sciences, Inc. - Marketing Mix: Price

Gilead Sciences, Inc. set Livdelzi at $12,606 per 30-day supply.

$12,606 x 12 = $151,272 per year.

HIV voluntary licenses covered 6 generic manufacturers and 120 countries.

The DOJ and HHS PrEP patent arrangement involved 2 federal agencies.

• $12,606 per 30-day supply for Livdelzi
• $151,272 annualized at 12 fills
• 6 generic manufacturers under HIV voluntary licenses
• 120 countries covered by HIV voluntary licenses
• 2 federal agencies in the DOJ/HHS PrEP patent arrangement